<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04043312</url>
  </required_header>
  <id_info>
    <org_study_id>833561</org_study_id>
    <nct_id>NCT04043312</nct_id>
  </id_info>
  <brief_title>Magnetic Stimulation to Treat VT Storm</brief_title>
  <acronym>STAR-VT</acronym>
  <official_title>A Randomized Controled Trial of Transcutaneous Magnetic Stimulation of the Stellate Ganglion to Treat Ventricular Tachycardia Storm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ventricular Tachycardia storm is a medical emergency characterized by three or more episodes&#xD;
      of ventricular arrhythmia within 24 hours and associated with a significantly increased&#xD;
      mortality and massive health resource utilization. Several therapies are utilized including&#xD;
      sympathetic blockade (through deep sedation and beta blockers), antiarrhythmic drugs,&#xD;
      implantable cardioverter defibrillator (ICD) reprograming where applicable, and catheter&#xD;
      ablation. Despite standard intervention, mortality rates remain high and additional&#xD;
      therapeutic options are actively being investigated.&#xD;
&#xD;
      The overall objective of this proposal is to investigate whether transcutaneous magnetic&#xD;
      stimulation designed to inhibit the left stellate ganglion can be used in this population.&#xD;
      This is a single-center, randomized, sham-controlled trial to assess the efficacy of&#xD;
      transcutaneous magnetic stimulation of the left stellate ganglion to treat patients with&#xD;
      ventricular tachycardia storm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventricular Tachycardia - Incidence of ventricular tachycardia on inpatient telemetry monitoring</measure>
    <time_frame>24-hours following completion of the protocol</time_frame>
    <description>Incidence of ventricular tachycardia on inpatient telemetry monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardioversion - Incidence of ICD or external defibrillation following stimulation on device interrogation or telemetry</measure>
    <time_frame>48-hours following completion of the protocol</time_frame>
    <description>Incidence of ICD or external defibrillation following stimulation on device interrogation or telemetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ICD or pacemaker lead impedances</measure>
    <time_frame>Immediately following completion of the protocol</time_frame>
    <description>Change in lead impedance (unit: Ohms) on device interrogation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ICD or pacemaker lead thresholds</measure>
    <time_frame>Immediately following completion of the protocol</time_frame>
    <description>Change in lead thresholds (unit: mV) on device interrogation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ICD or pacemaker lead sensitivities</measure>
    <time_frame>Immediately following completion of the protocol</time_frame>
    <description>Change in lead sensitivity (unit: mA) on device interrogation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local effect from stimulation - Incidence of local skin irritation or patient reported local discomfort on visual analog scale (1-10)</measure>
    <time_frame>Immediately following completion of the protocol</time_frame>
    <description>Incidence of local skin irritation or patient reported local discomfort on visual analog scale (1-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiarrhythmic drugs used post stimulation - Incidence of antiarrhythmic drug use post stimulation per inpatient medical record</measure>
    <time_frame>72 hours following completion of the protocol</time_frame>
    <description>Incidence of antiarrhythmic drug use post stimulation per inpatient medical record</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients will receive one hour of sham stimulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive one hour of active magnetic stimulation to the left stellate ganglion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magstim SuperRapid</intervention_name>
    <description>Transcutaneous magnetic stimulation targeting the left stellate ganglion.</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magstim SuperRapid</intervention_name>
    <description>Sham transcutaneous magnetic stimulation.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  â‰¥ 3 episodes of VT in 24 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Implanted ventricular assist device&#xD;
&#xD;
          -  Metal implanted in head or neck (except the mouth)&#xD;
&#xD;
          -  Implanted medication pumps&#xD;
&#xD;
          -  Cochlear implant&#xD;
&#xD;
          -  Implanted brain stimulator&#xD;
&#xD;
          -  Ocular implant&#xD;
&#xD;
          -  History of malignancy in region of stimulation (neck)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Timothy Markman, MD</last_name>
    <phone>2675930103</phone>
    <email>timothy.markman@pennmedicine.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Markman, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2019</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

